REINACH & BASEL, Switzerland--(BUSINESS WIRE)--Nitec Pharma AG today announced the results of the CAPRA-1 study, showing a reduction of morning stiffness by more than 50% on average in patients with rheumatoid arthritis (RA) treated with Lodotra™ for up to 12 months. The data of this study will be presented today at the 2007 Annual Scientific Meeting of the American College of Rheumatology (ACR) in Boston MA, USA.
